HERON THERAPEUTICS INC. overview

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO, May 29, 2024 SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF ® (bupivacaine and meloxicam) extended-release solution Vial...

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire SAN DIEGO, May 7, 2024 Net Product Sales of $34.7 million , which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02) , which decreased from $(0.27) for the same period in 2023. Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF ® promotional efforts in the first quarter of 2024. Gross Margin improved to 76% for the...

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 PR Newswire SAN DIEGO, April 24, 2024 SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024 , at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by...

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire SAN DIEGO, April 11, 2024 SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET . The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and...

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO, March 28, 2024 SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard , Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024 , at 11:00 AM ET at the 23 rd Annual Needham Virtual Healthcare Conference. The conference is being...

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates PR Newswire SAN DIEGO, March 12, 2024 2023 oncology care franchise revenue was $107.9 million , exceeding full-year 2023 guidance ZYNRELEF ® achieved quarterly record of $5.6 million in Q4 Net Product Sales Ended 2023 with cash and cash equivalents of $80.4 million Announced partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF promotional efforts on January 7,...

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 PR Newswire SAN DIEGO, Feb. 28, 2024 SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, March 12, 2024 , at 4:30 p.m. ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights. The...

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures PR Newswire SAN DIEGO, Jan. 23, 2024 – Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New...